Título : |
The establishment of public health policies and the burden of non-alcoholic fatty liver disease in the Americas |
Tipo de documento : |
documento electrónico |
Autores : |
Juan Carlos Restrepo Gutiérrez, |
Fecha de publicación : |
2022 |
Títulos uniformes : |
The Lancet Gastroenterology and Hepatology
|
Idioma : |
Inglés (eng) |
Resumen : |
Non-alcoholic fatty liver disease (NAFLD) affects 20–25% of the general population and is associated with morbidity, increased mortality, and elevated health-care costs. Most NAFLD risk factors are modifiable and, therefore, potentially amenable to being reduced by public health policies. To date, there is no information about NAFLD-related public health policies in the Americas. In this study, we analysed data from 17 American countries and found that none have established national public health policies to decrease NAFLD-related burden. There is notable heterogeneity in the existence of public health policies to prevent NAFLD-related conditions. The most common public health policies were related to diabetes (15 [88%] countries), hypertension (14 [82%] countries), cardiovascular diseases (14 [82%] countries), obesity (nine [53%] countries), and dyslipidaemia (six [35%] of countries). Only seven (41%) countries had a registry of the burden of NAFLD, and efforts to raise awareness in the Americas were scarce. The implementation of public health policies are urgently needed in the Americas to decrease the burden of NAFLD. |
Mención de responsabilidad : |
Luis Antonio Díaz, MD, Eduardo Fuentes-López, PhD, Gustavo Ayares, MD, Francisco Idalsoaga, MD, Jorge Arnold, MD, Andrea Márquez-Lomas, MD, Carolina A Ramírez, MD, María Paz Medel, MD, Francisca Viñuela, BS, Lucas Lacalle, BS, Juan Pablo Roblero, MD, Prof Catterina Ferreccio, PhD, Mariana Lazo, MD, Mayur Brahmania, MD, Prof Ashwani K Singal, MD, Melisa Dirchwolf, MD, Prof Nahum Méndez-Sánchez, MD, Norberto Chavez-Tapia, MD, Patricia Guerra, MD, Juan Carlos Restrepo, MD, Claudia P Oliveira, MD, Julissa Lombardo, MD, Abel Sánchez, MD, Martín Elizondo, MD, Prof Martín Tagle, MD, Martín Padilla, MD, Marco Sánchez, MD, Enrique Carrera, MD, Marcos Girala, MD, Omega Chery, MD, Marlen Castellanos-Fernández, MD, Francisco Barrera, MD, Prof Jeffrey V Lazarus, PhD, Prof Patrick S Kamath, MD, Prof Ramon Bataller, MD, Prof Marco Arrese, MD, Juan Pablo Arab, MD |
Referencia : |
Lancet Gastroenterol Hepatol. 2022 Jun;7(6):552-559. |
DOI (Digital Object Identifier) : |
10.1016/S2468-1253(22)00008-5 |
PMID : |
35430032 |
En línea : |
https://linkinghub.elsevier.com/retrieve/pii/S2468125322000085 |
Enlace permanente : |
https://hospitalpablotobon.cloudbiteca.com/pmb/opac_css/index.php?lvl=notice_display&id=6019 |
The establishment of public health policies and the burden of non-alcoholic fatty liver disease in the Americas [documento electrónico] / Juan Carlos Restrepo Gutiérrez, . - 2022. Obra : The Lancet Gastroenterology and HepatologyIdioma : Inglés ( eng) Resumen : |
Non-alcoholic fatty liver disease (NAFLD) affects 20–25% of the general population and is associated with morbidity, increased mortality, and elevated health-care costs. Most NAFLD risk factors are modifiable and, therefore, potentially amenable to being reduced by public health policies. To date, there is no information about NAFLD-related public health policies in the Americas. In this study, we analysed data from 17 American countries and found that none have established national public health policies to decrease NAFLD-related burden. There is notable heterogeneity in the existence of public health policies to prevent NAFLD-related conditions. The most common public health policies were related to diabetes (15 [88%] countries), hypertension (14 [82%] countries), cardiovascular diseases (14 [82%] countries), obesity (nine [53%] countries), and dyslipidaemia (six [35%] of countries). Only seven (41%) countries had a registry of the burden of NAFLD, and efforts to raise awareness in the Americas were scarce. The implementation of public health policies are urgently needed in the Americas to decrease the burden of NAFLD. |
Mención de responsabilidad : |
Luis Antonio Díaz, MD, Eduardo Fuentes-López, PhD, Gustavo Ayares, MD, Francisco Idalsoaga, MD, Jorge Arnold, MD, Andrea Márquez-Lomas, MD, Carolina A Ramírez, MD, María Paz Medel, MD, Francisca Viñuela, BS, Lucas Lacalle, BS, Juan Pablo Roblero, MD, Prof Catterina Ferreccio, PhD, Mariana Lazo, MD, Mayur Brahmania, MD, Prof Ashwani K Singal, MD, Melisa Dirchwolf, MD, Prof Nahum Méndez-Sánchez, MD, Norberto Chavez-Tapia, MD, Patricia Guerra, MD, Juan Carlos Restrepo, MD, Claudia P Oliveira, MD, Julissa Lombardo, MD, Abel Sánchez, MD, Martín Elizondo, MD, Prof Martín Tagle, MD, Martín Padilla, MD, Marco Sánchez, MD, Enrique Carrera, MD, Marcos Girala, MD, Omega Chery, MD, Marlen Castellanos-Fernández, MD, Francisco Barrera, MD, Prof Jeffrey V Lazarus, PhD, Prof Patrick S Kamath, MD, Prof Ramon Bataller, MD, Prof Marco Arrese, MD, Juan Pablo Arab, MD |
Referencia : |
Lancet Gastroenterol Hepatol. 2022 Jun;7(6):552-559. |
DOI (Digital Object Identifier) : |
10.1016/S2468-1253(22)00008-5 |
PMID : |
35430032 |
En línea : |
https://linkinghub.elsevier.com/retrieve/pii/S2468125322000085 |
Enlace permanente : |
https://hospitalpablotobon.cloudbiteca.com/pmb/opac_css/index.php?lvl=notice_display&id=6019 |
| |